
We’re back to covering the ongoing saga of Universal Ostrich Farms, and the CFIA’s attempt to cull (kill) approximately 400 birds on a B.C. farm. The story keeps getting stranger. An Appeal is underway to challenge a Federal Court ruling, permitting it to go ahead.
See Parts 1, 2, 3, 4 and 5 in the series for more information.
The Appeal was initiated in late May to set aside Justice Zinn’s ruling, which upheld the Canada Food Inspection Agency’s (CFIA’s) cull order as “reasonable”. The last article mentioned the sort of concerns that will be raised at the hearing.
But before that, there’s another more immediate problem. Unless otherwise halted, the current cull order is set to go into effect. A Motion was recently filed in order to prevent that, at least for the time being.
The Motion includes Affidavits from Karen Espersen and David Bilinski, in addition to the Notice, and the written arguments.
Such a Motion would likely not involve a hearing. Instead, a single Judge would consider all the filings and issue a decision behind closed doors.
Beyond simply requesting that the culling be deferred, the Motion reveals a lot about the operation that wasn’t previously public (or at least well known).
Motion To Stay Culling Is Well Written
To be more balanced, the filings submitted here are of better quality than what is usually covered on this website. At the end of January, 2025, Justice Battista did temporarily stay the killing of the ostriches. It’s reasonable to assume that the Court of Appeal may as well. While not guaranteed, it’s quite possible.
UOF’s argument to postpone the culling amounts to the following:
- This appeal is neither frivolous nor vexatious
- UOF will suffer irreparable harm if its ostriches are slaughtered
- UOF will suffer the greater harm if a stay is denied
The full Motion Record is available, and includes all the documents. The Notice of Appeal outlines a number of serious errors, such as Justice Zinn not fully understanding the arguments that were before him. It’s stated that he deferred far too much to the CFIA, instead of diving more into the evidence himself. Beyond that, there are allegations (albeit not fleshed out) of financial conflicts of interest with prior counsel.
The Motion further requests that additional testing be done on the birds to see if there are illnesses that may have spread. It’s offered that the Appellants would cover such expenses.
The Motion points out the obvious: if the stay isn’t granted, and the birds are culled anyway, then the entire Appeal becomes moot. There would be no birds left to save.
In fairness though, the CFIA did appeal the Order of Justice Battista at the end of January. It was dropped for being “moot” after Justice Zinn upheld the CFIA order as reasonable. It’s fair to assume that the CFIA will be opposing such a Motion this time around as well.
Bilinski Affidavit Sheds New Light On Business Operations



The Affidavit of David Bilinski is very interesting. It outlines in considerable detail where he and Karen anticipated taking the business to, and whom they would be partnering with. Exhibit “E” is the business plan that was submitted.
An important detail is that the agreement with Breathe Medical fell through when the company declared bankruptcy. The partnership with the Quebec-based Immune Biosolutions appears to have not fared well either. However, there were apparently other options available.
19. By December 2020, UOF’s operations became entirely dedicated to scientific research through antibody production.
20. In Early 2021, Breathe Medical Manufacturing declared bankruptcy and our exclusive supply agreement and corresponding revenue expectations were not realized.
21. In 2022, Karen and I incorporated Struthio Bio Science Inc. (“Struthio”) to, in partnership with UOF, engage in manufacturing and marketing of ostrich egg IgY antibodies and related products. As of the date of this Affidavit, Struthio is wholly owned by Karen and I with each of us holding a 50% share.
22. In April 2024, Karen and I negotiated and entered into agreements which would, inter alia, implement a new ownership structure for Struthio. Under this proposed restructuring, an majority interest in Struthio would be transferred to new principals and governed by a board of directors, including Dr. Tsukamoto – in exchange for investment and the licensing of certain patents necessary for commercialization of IgY antibodies and related products.
23. Exhibit “E” to this affidavit is a true copy of the Struthio BioScience Business Plan dated December 5, 2023 (“Struthio Business Plan”) and accompanying PowerPoint presentation. The Struthio Business Plan is a detailed roadmap for Struthio’s venture to develop and commercialize biomedical products derived from ostrich eggs, and it identifies UOF as a crucial partner supplying the necessary ostrich eggs. Among other things, the plan describes Struthio’s proposed proprietary research into antibodies from ostrich egg yolks, new corporate and governance structure and projects the financial returns from this research over the next several years (in the order of millions of dollars annually). Karen and I would retain 25% each interest in Struthio BioScience Inc.
24. I do not put this forward to assert that those revenue projections will in fact be realized or that the science will succeed. Rather, I rely on the Struthio Business Plan to show the existence of Struthio’s business model and the expectations that UOF and Struthio had at the time: namely, that UOF’s ostrich flock would be used to produce a continuous supply of eggs enabling Struthio’s venture to move forward. The very inclusion of UOF as a key supplier in this plan, and the magnitude of the projected benefits, demonstrate how integral our ostrich flock is to UOF’s commercial strategy with Struthio. The plan provides important context for UOF’s anticipated growth – context which will be completely upended if the flock is destroyed. Any statements or figures in the business plan are being referenced here only to illustrate what Struthio anticipated and the scale of the opportunity UOF stood to gain, not as proof that those outcomes are guaranteed.
25. Exhibit “F” to this affidavit is a true copy of the terms of Struthio and Ostrich Pharma KK (“OPKK”) Agreement (“OPKK Agreement”) which was executed On April 11, 2024.
26. The OPKK Agreement sets out the principal terms of a proposed investment and partnership whereby OPKK agreed in principle to partner with Struthio’s egg-based biotech venture. The OPKK Agreement references anticipated investment, exclusive patent licencing, technology transfer and a revised corporate structure for Struthio. This reflects that OPKK’s confidence in Struthio’s business which was inextricably predicated on UOF’s ostrich flock and egg production.
Do read Bilinski’s Affidavit, especially the business plan which was attached as Exhibit “E”.
- Chairman – Dr. Yasuhiro Tsukamoto- President of Kyoto University, Founder and Scientist of Ostrich IgY patents
- CEO – Interm – Dave Bilinski – Presently recruiting for full time position – Production Expert for Ostrich, 31 Years experience
- VP – IgY Egg Production – Karen Espersen -, IgY Egg Production Expert for Ostrich, Director Alberta Ostrich Association, 33 Years experience
- VP Product Development – Dr. Stu Greenberg –, CEO Ostrich Pharma USA
- Board Member – Dr. Lyle Oberg – Presently Chariman of Alberta Health Services
- CF0 – Actively recruiting for position
- CMO – Carol Epstein, M.D. .Dr. Epstein has been in the biopharmaceutical industry for over 25 years. She has served as Chief Medical Officer of IRX Therapeutics, Inc
- Board Member – To be chosen by investor
- Dr. Alessio Fasano- Director of Center for Celiac Research & Treatment at MassGeneral Hospital. Director of the Mucosal Immunology and Biology Research Center at MassGeneral Hospital for Children (50 scientists and staff). Founder of Zonulin
- Dr. Meer Janjua – BioNektar Inc. Founder and Chief Medical Officer, International Distribution management through Doctors network
- Dr. Willian Bithoney MD, FAAP – Dr. William Bithoney is an experienced healthcare professional with more than 35 years of experience in the healthcare sector having served as a physician executive in diverse academic and hospital systems
- Dr. Elma Hawkins, Ph.D. – Dr. Hawkins’s 30-year career encompasses pioneering efforts in biotechnology and drug development, and executive roles in corporate development, strategy, fundraising, and general management
- Hassan Hassan = Business Development – CEO of Aim-X Canada. Dedicated International Entrepreneur in Natural Resource Exploration & Sustainable Development
- Ken Davidson , CPA, CA, CFP, ICD.D -Ken Davidson is an accomplished corporate director, consultant, entrepreneur, Chartered Professional Accountant (CPA) and certified Corporate Director (ICD.D) with over 30 years of experience in a diverse range of industries across Canada, the US and the Caribbean
Currently, Espersen and Bilinski co-own Struthio BioSciences, holding 50% each. The proposed new structure would see that reduced to 25% each, and a more corporate format. Bilinski would become the CEO, at least on an interim basis. Espersen would be a Vice President. This is a far cry from the “family farm” that had been portrayed by media outlets.
Wasn’t this supposed to be about protecting the food supply?
Considering the disdain that the Freedom Movement has for “public health” in general, it seems odd to be supporting the expansion of an enterprise that would see the Chairman of Alberta Health Services become one of the Directors.
In other words, donors are contributing to these legal proceedings in order to protect the expansion of a company engaged in scientific research. These ostriches are test subjects, plain and simple.
At this point, one should ask what benefit donors are getting from contributing to this case. Consider that Bilinski and Espersen were willing to give outsiders a 50% stake in the new company. What would be fair to people contributing to these legal proceedings? Should larger donations merit equity, or dividends?
Silence From “Alternative Media” Outlets
Espersen and Bilinski have every right to earn a living. However, when donations are solicited, there’s an expectation that there will be transparency. While this Motion does shed a lot of light on their business model, it seems unlikely that contributors were fully aware of it.
It’s a fair question to ask if Universal Ostrich Farms will even exist a few years from now, regardless of what the CFIA does. Espersen doesn’t own the land, and the Quigleys are trying to kick them out. Yes, it’s still being disputed in Court in B.C., but still worth asking.
Would people be protesting around the farm’s perimeter if they knew these details? Would they (or their children) feel safe around animals injected with experimental antigens? People need to know what else — if anything — these birds were exposed to.
Druthers, among others, did cover the story, and report on these birds being the solution for “natural immunity”. Covid doesn’t exist, but that’s beside the point here. While Kyoto University was mentioned, there was nothing about where the parties planned to take their relationship.
The proposed trajectory is open-ended pharmaceutical testing, where ostriches will be little more than guinea pigs. Again, this is the kind of thing many in the Freedom Movement are against.
A follow-up from Connie would also be nice.
COURT OF APPEAL (CHALLENGING JUSTICE ZINN’S ORDER)
(1) Ostrich APPEAL Notice Of Appeal (May, 2025)
(2) UOF APPEAL Notice Of Appearance (May, 2025)
COURT OF APPEAL (MOTION TO STAY CULL ORDER)
(1) UOF APPEAL Motion Record To Stay Culling (June, 2025)
(2) UOF APPEAL Notice Of Motion To Stay Culling (June, 2025)
(3) UOF APPEAL Bilinski Affidavit To Stay Culling (June, 2025)
(4) UOF APPEAL Bilinski Affidavit Exhibit E June, 2025)
(5) UOF APPEAL Espersen Affidavit To Stay Culling (June, 2025)
(6) UOF APPEAL Moving Party Submissions To Stay Culling (June, 2025)
COURT OF APPEAL (JUSTICE BATTISTA STAYING CULL ORDER):
(1) UOF Order To Stay Culling (January, 2025)
(2) UOF Notice Of Appeal (February, 2025)
(3) UOF Notice Of Appearance (February, 2025)
(4) UOF Agreement Appeal Book Contents (March, 2025)
(5) UOF Joint Appeal Book (April, 2025)
(6) UOF Consent To Extend Time (May, 2025)
(7) UOF Notice Of Discontinuance (May, 2025)
FEDERAL COURT DOCUMENTS (CFIA):
(1) Ostrich Notice Of Application Certified (January, 2025)
(2) Ostrich Notice Of Application (January, 2025)
(3) Ostrich Notice Of Motion (January, 2025)
(4) Ostrich Bilinski Affidavit (January, 2025)
(5) Ostrich Espersen Affidavit (January, 2025)
(6) Ostrich Pelech Affidavit (January, 2025)
(7) Ostrich Jones Affidavit (January, 2025)
(8) Ostrich Responding Motion Record (January, 2025)
(9) Ostrich Responding Motion Record Expedited (February, 2025)
(10) Ostrich Motion Record Ex-Parte (February, 2025)
(11) Ostrich Exemption Notice Of Application (February, 2025)
(12) Ostrich Exemption Motion Record (February, 2025)
(13) Ostrich Ruling Of Justice Zinn (May, 2025)
MONEY:
(1) https://bcrising.ca/save-our-ostriches/
(2) https://www.gofundme.com/f/help-ostrich-farmers-fight-to-save-herd-from-avian-flu?attribution_id=sl%3A80e09934-7413-429b-acfb-2f7015cc19d3&lang=en_CA
(3) https://www.givesendgo.com/save-our-ostriches
(4) https://www.kinexus.ca/

























